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Abstract
Background: Patients with inflammatory joint diseases tend due to new treatments to be more
physically active; something not taken into account by currently used outcome measures. The
Rheumatoid and Arthritis Outcome Score (RAOS) is an adaptation of the Knee injury and
Osteoarthritis Outcome Score (KOOS) and evaluates functional limitations of importance to
physically active people with inflammatory joint diseases and problems from the lower extremities.
The aim of the study was to test the RAOS for validity, reliability and responsiveness.
Methods: 119 in-patients with inflammatory joint disease (51% RA) admitted to multidisciplinary
care, mean age 56 (±13), 73% women, mean disease duration 18 (±14) yr were consecutively
enrolled. They all received the RAOS, the SF-36, the HAQ and four subscales of the AIMS2 twice
during their stay for test of validity and responsiveness. Test-retest reliability of the RAOS
questionnaire was calculated on 52 patients using the first or second administration and an
additional mailed questionnaire.
Results: The RAOS met set criteria of reliability and validity. The random intraclass correlation
coefficient (ICC 2,1) for the five subscales ranged from 0.76 to 0.92, indicating that individual
comparisons were possible except for the subscale Sport and Recreation Function. Inter-item
correlation measured by Cronbach's alpha ranged from 0.78 to 0.95. When measuring construct
validity the highest correlations occurred between subscales intended to measure similar
constructs. Change over time (24 (± 7) days) due to multidisciplinary care was significant for all
subscales (p < 0.001). The effect sizes ranged from 0.30–0.44 and were considered small to
medium. All the RAOS subscales were more responsive than the HAQ. Some of the SF-36
subscales and the AIMS2 subscales were more responsive than the RAOS subscales.
Conclusion: It is possible to adapt already existing outcome measures to assess other groups with
musculoskeletal difficulties in the lower extremity. The RAOS is a reliable, valid and responsive
outcome instrument for assessment of multidisciplinary care. To fully validate the RAOS further
studies are needed in other populations.
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Background
The rheumatic diseases include both inflammatory and
non-inflammatory conditions. The chronic inflammatory
diseases are all characterized by joint pain, joint swelling,
morning stiffness, limitation of range of joint motion and
in many cases a progressing physical impairment. The
chronic inflammatory rheumatic diseases include a
number of different diagnoses such as rheumatoid arthri-
tis (RA), juvenile chronic polyarthritis and spondyloar-
thropathies [1].
Thanks to new treatments of inflammatory joint diseases
the patients stay more alert and live a more active life
compared to 10–20 years ago [2–4]. This change in phys-
ical status calls for assessment of items related to more dif-
ficult functions, such as sport and recreational activities.
There are no self-administered questionnaires for lower
limb function and chronic inflammatory joint diseases
that take hip, knee and foot into account and at the same
time relate to sport and recreational activities or to leg-
related quality of life.
Functional disability and quality of life are key outcomes
that influence the patients' compliance and satisfaction
with the treatment and such measures should be based on
self-assessment [5,6]. The Knee Injury and Osteoarthritis
Outcome Score (KOOS) [7] is a self-administered exten-
sion of the WOMAC [8], and the validity, reliability and
responsiveness has been found good in different popula-
tions with knee injuries and knee osteoarthritis [7,9–11].
The Foot and Ankle Outcome Score (FAOS) is an adapta-
tion of the KOOS intended to evaluate symptoms and
functional limitations related to the foot and ankle. The
FAOS meet set criteria of validity and reliability [12]. The
Hip Disability and Osteoarthritis Outcome Score
(HOOS), another adaptation of the KOOS for people
with hip osteoarthritis has also been shown to meet set
criteria of validity and responsiveness [13]. The question
was raised if the KOOS could be adapted and used to eval-
uate the outcome of patients with chronic inflammatory
joint diseases and problems from the lower extremities.
The aim of the study was to test the reliability, validity and
responsiveness of the Rheumatoid and Arthritis Outcome
Score (RAOS), an adapted version of the KOOS, applied
to people with chronic inflammatory joint disease and
problems from the lower extremity.
Methods
An already existing questionnaire (Knee injury and Oste-
oarthritis Outcome Score, KOOS) was adapted for use in
patients with inflammatory joint diseases by exchanging
the word knee with leg in all the questions, no items were
added or removed. The adapted questionnaire was called
the Rheumatoid and Arthritis Outcome Score, RAOS.
Firstly, the RAOS was reviewed by an expert panel to
ensure face and content validity. Secondly the question-
naire was tested in a clinical study for assessing construct
validity, reliability and responsiveness.
Expert panel
Thirteen patients with chronic inflammatory joint disease,
11 women and 2 men, mean age 56 (range 31 – 76), mean
years of disease 14 (range 3.5 – 37), acted (after informed
consent) as an expert panel to give the RAOS question-
naire face and content validity. Both in and outpatients
were asked to participate, the emphasis put on a variety in
age and years of disease. There was no set number of peo-
ple who should be interviewed. The criterion 'sampling
redundancy' was used; interviewing people until no new
themes emerged [14] (Figure 1). In addition, two medical
doctors and five physical therapists reviewed the
questionnaire.
Development of the RAOS questionnaire
To assess content validity of the items the patients were
asked to rate the relevance or importance of each item on
a scale from one to three where: 1 = irrelevant, unimpor-
tant; 2 = somewhat relevant, somewhat important; 3 =
very relevant, very important. It was considered that the
mean score should be at least 2.0 (possible range 1.0 to
3.0) to justify inclusion into the RAOS. The same proce-
dure was used when the KOOS was adapted for use in
patients with problems related to the foot and ankle (the
FAOS) [12]. The patients were asked to add items thought
to be missing.
The expert panel added no items. However, due to diffi-
culty acknowledging problems specifically related to the
The adaptation and validation process of the Rheumatoid  Arthritis Outcome Score (RAOS) Figure 1
The adaptation and validation process of the Rheumatoid 
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leg, the word was explained with hip, knee and foot where
possible in the final RAOS questionnaire. All items had a
relevance score over 2.0, the set criteria for inclusion in the
RAOS, and no items were excluded because of poor con-
tent validity The mean relevance score of all included
items was 2.7 (range 2.4 – 3.0).
The RAOS questionnaire
The Rheumatoid and Arthritis Outcome Score (RAOS) is
an adaptation of the Knee injury and Osteoarthritis Out-
come Score (KOOS), intended to evaluate symptoms and
functional limitations of importance to people with
chronic inflammatory joint diseases and problems from
lower extremities. The RAOS is a self-administered instru-
ment and consists of 42 items assessing five separate
patient-relevant dimensions: Pain (nine items); Other
Symptoms like stiffness, swelling, and range of motion
(seven items); Activities of Daily Living (ADL) (17 items);
Sport and Recreational activities (Sport/Rec) (five items);
and lower limb-related Quality of Life (QOL) (four
items). The questions from the Western Ontario and Mac
Master Universities (WOMAC) Osteoarthritis Index LK
3.0 [8] are included in their full and original form and
WOMAC scores can thus be calculated from the RAOS
questionnaire.
Five Likert-boxes were used (no, mild, moderate, severe,
extreme) to answer each question. All items have a possi-
ble score from zero to four, and each of the five subscale
scores is calculated as the sum of the items included. Raw
scores are then transformed to a zero to 100, worst to best,
scale. If a mark was placed outside a Likert-box the closest
box was used. If two boxes were marked, the one indicat-
ing more severe problems was chosen. Missing data were
treated as such; one or two missing values were substi-
tuted with the average value for the dimension. If more
than two items were omitted, the response was considered
invalid. The scores of the different subscales can be pre-
sented graphically as a RAOS profile. The RAOS question-
naire, user's guide and scoring manual can be
downloaded from http://www.koos.nu.
Clinical study
A clinical study was designed to assess construct validity,
reliability and responsiveness of the RAOS questionnaire.
The study took place at Spenshult Hospital for Rheumatic
Diseases, outside Halmstad in the southwest of Sweden.
Subjects
119 consecutively enrolled in-patients at Spenshult Hos-
pital, mean age 56 (range 20 – 85), 73% women, mean
disease duration 18 years (range 0.3 – 61), mean HAQ
disability score 1.3 (range 0 – 2.88) were included in the
study. Sixty-one of the patients were diagnosed with rheu-
matoid arthritis (RA) according to the ACR 1987 criteria
[15]. The other 58 patients had an inflammatory joint dis-
ease other than RA; spondyloarthropathies (n = 24), pol-
yarthritis (n = 4), psoriatic arthritis (n = 15), polymyalgia
reumatica (n = 2), Sjögren's syndrome (n = 5), Reiter's dis-
ease (n = 1), juvenile chronic arthritis (n = 6) and mixed
connective tissue disease (n = 1) (Table 1). Patients under-
going post-operative rehabilitation were not asked to par-
ticipate in the study.
All patients underwent exercise therapy and multidiscipli-
nary team care during their stay at Spenshult. The physical
training consisted of individual and group exercise led by
a physical therapist.
Questionnaires
The SF-36 is a widely used generic instrument for assess-
ment of health status. It is patient-administered and
comprises eight subscales assessing physical and mental
health to various degrees (Physical Function, Role-Physi-
cal, Bodily Pain, General Health, Vitality, Social Function-
ing, Role-Emotional and Mental Health) [16]. The
Swedish acute version 1.0 was used [17].
Table 1: Patient characteristics
Arthritis Total n = 119 Reumatoid Arthritis n = 
61
Inflammatory joint 
disease other than RA n 
= 58
Age in years; mean (SD) 56 (13) 61 (12) 50 (13)
Women; n, (%) 87 (73%) 47 (77%) 40 (69%)
Mean HAQ disability score; mean (SD) 1.3 (0.7) 1.4 (0.7) 1.1 (0.6)
Self-report of problem from the upper extremity % 100% 100% 100%
Self-report of problems from the lower extremity % 99% 100% 98%
Disease duration in years; mean (SD) 18 (14) 19 (14) 17 (14)
Days between questionnaires; mean (SD) 24 (7) 23 (5) 25 (8)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/55
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The HAQ is a self-administered, disease-specific question-
naire. HAQ contains 20 items and assesses the degree of
difficulty in performing activities of daily living during the
last week. The activities are grouped into eight dimen-
sions; Dressing and Grooming, Arising, Eating, Walking,
Hygiene, Reach, Grip and Other Activities [18]. The HAQ
is translated and validated for Swedish conditions [19].
The AIMS2 consists of 57 items. It can be divided into 12
scales: Mobility Level, Walking and Bending, Hand and
Finger function, Arm Function, Self-Care Tasks, House-
hold Tasks, Social Activities, Support from Family and
Friends, Arthritis Pain, Work, Level of Tension and Mood.
Together with questions about perceived current and
future health and demographic data, it consists of a total
of 78 items. The different subscales can be used solemnly
[20,21].
Validity
The Short Form 36-item of the Medical Outcome Study
(SF-36 acute version) [16], the Stanford Health Assess-
ment Questionnaire (HAQ) [18], and four subscales of
the Arthritis Impact Measurement Scale (AIMS2) [20]
(Walking and Bending, Arm Function, Arthritis Pain,
Level of Tension) were administered at baseline for deter-
mination of construct validity. High, medium or low cor-
relations with the SF-36, the HAQ and the AIMS2 were
hypothesized  a priori. The highest correlations were
expected when comparing scales intended to measure the
same or similar constructs. We expected to observe higher
correlations between the SF-36 Physical Function and the
RAOS subscales ADL and Sport/Recreation than between
SF-36 Role-Emotional and Mental Health compared to all
the five RAOS subscales. The HAQ is a measure of ADL
disability and were expected to have higher correlations to
the RAOS subscale ADL than to the other RAOS subscales.
For the AIMS2 the highest correlations where expected
between Walking and Bending and RAOS subscale ADL
and Sport/Recreation and also between AIMS2 Arthritis
Pain and RAOS Pain. Lower correlations were expected
between AIMS2 Arm Function and RAOS subscales Symp-
toms and Sport/Recreation since they do not measure
similar constructs. Spearman's correlation coefficient (rs)
was used to assess construct validity [14,22]. When vali-
dating patient-relevant questionnaires, correlation coeffi-
cients between similar constructs often fall between 0.2
and 0.6 and rarely above 0.7 [23].
Floor and ceiling effects were assessed on the first admin-
istration of the RAOS for determination of content
validity.
Reliability
To assess test-retest reliability, 67 of the enrolled patients
had the RAOS questionnaire sent home, either prior to
admittance (n = 17) or after discharge (n = 50). Since no
differences were seen in the results between these two
groups, the results are reported for both groups together.
A maximum of 15 days were allowed between the two
assessments to minimize the influence of change in
clinical status [14]. The test-retest reliability was calcu-
lated using the random-effects intraclass correlation coef-
ficient (ICC2.1) [14]. One suggestion for acceptable test-
retest reliability for assessment of an individual is an intra
class correlation coefficient of 0.85 [24]. When comparing
groups, a lower intra class correlation coefficient is likely
acceptable and a limit of 0.75 has been suggested [25].
According to Bland and Altman repeatability can be
shown when plotting the difference against the mean of
the two assessments for each subject. 95% of the differ-
ences are expected to be less than two standard deviations
[26].
Internal consistency is an alternative approach to deter-
mine reliability, which is obtained from a single applica-
tion of the technique and suggested because of the
dynamic nature of many chronic diseases. A test with high
inter-item correlation is homogenous and is likely to pro-
duce consistent responses [22]. Inter-item correlation was
assessed on the baseline administration of the RAOS by
calculation of Cronbach's alpha [14,22]. A Cronbach's
alpha of ≥ 0.80 is generally regarded as acceptable [22].
Responsiveness
The patients completed the RAOS, the SF-36, the HAQ
and four subscales of the AIMS2 at baseline and at the end
of the multidiscipline care intervention, shortly before
leaving Spenshult. Change due to intervention, was
assessed by Wilcoxon's signed rank test. Responsiveness
was calculated by effect size. Effect size was defined as
mean score change divided by the standard deviation of
the baseline score [22]. Although there are no absolute
standards for effect size it has been suggested that in com-
parative studies examples of small, medium, and large
effect sizes might have values of 0.2, 0.5, 0.8, respectively
[22].
Statistics
In the literature there is a lack of consensus on how to cal-
culate reliability, validity and responsiveness of a ques-
tionnaire. The data obtained from questionnaires such as
RAOS are ordinal and implies the use of non-parametric
statistics. Statistical analyses of internal consistency have
been made using parametric statistics as suggested by both
Bellamy and Streiner [14,22]. The use of non-parametric
statistics while checking for test retest reliability implies
the use of the Kappa coefficient. If a quadratic weighting
scheme is used, then the weighted kappa is exactly identi-
cal to the intraclass correlation coefficient (ICC) [14].Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/55
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Where parametric statistics have been used there were no
differences between the results of parametric and non-par-
ametric analyzes.
Analyses were carried out in both groups of patients (RA
and other inflammatory joint diseases). Since the inter-
pretation of the data was similar in both groups the results
from all 119 patients will be reported together. Statistical
significance was set to p < 0.05. The data was analyzed
using SPSS 11.5.
The Ethics committee at the Medical Faculty at Lund Uni-
versity approved the study.
Results
Missing baseline data
For all study subjects, responses to sixty-four items were
missing in the RAOS questionnaire (64 items of 42 items
× 119 patients = 1%). A total score could be calculated for
all 119 subjects for the subscale Pain, for 118/119 subjects
for the subscales Symptoms and Quality of Life, 117/119
subjects for Sport and Recreation and for the subscale ADL
a total score could be calculated for 116/119 subjects.
Validity
Score distribution. The number of patients receiving floor
or ceiling effects at baseline was low for the RAOS sub-
scales, with one exception. For the subscale Sport/Recrea-
Table 2: Floor and ceiling effects of the questionnaires The percentage of patients reporting worst possible score (floor effect) / best 
possible score (ceiling effect) for the RAOS, the SF-36, the AIMS2 and the HAQ at baseline.
Questionnaire Floor/Ceiling Questionnaire Floor/Ceiling
RAOS SF-36
Pain 0/3 Physical Function 4/1
Symptoms 0/2 Role Physical 64/10
ADL 0/2 Bodily Pain 7/1
Sport/Rec 37/1 General Health 2/1
QOL 3/1 Vitality 5/1
AIMS2 Walking / Bending 10/0 Social Functioning 1/21
Arm Function 1/18 Role Emotional 36/42
Arthritis Pain 5/1 Mental Health 1/4
Level of Tension 0/4 HAQ 0/3
Table 3: Construct validity Spearman's correlation coefficient (rs) determined when comparing RAOS five dimensions to the SF-36 
eight different subscales, HAQ and four subscales of AIMS2. Significant correlations, p < 0.05 in bold figures, all correlations over 0.32 
were significant at p < 0.01, n = 115–119.
Reumatoid and Arthritis Outcome Score (RAOS)
Pain Symptoms ADL Sport/Rec QOL
SF-36
Physical Function 0.56 0.47 0.65 0.63 0.53
Role Physical 0.31 0.18 0.38 0.18 0.26
Bodily Pain 0.57 0.34 0.56 0.21 0.46
General Health 0.35 0.27 0.35 0.20 0.33
Vitality 0.36 0.32 0.37 0.20 0.26
Social Functioning 0.34 0.21 0.37 0.12 0.27
Role Emotional 0.23 0.18 0.23 0.15 0.18
Mental Health 0.26 0.16 0.24 0.00 0.12
HAQ -0.51 -0.38 -0.72 -0.64 -0.51
AIMS2
Walking and Bending -0.54 -0.47 -0.63 -0.48 -0.50
Arm Function -0.38 -0.37 -0.46 -0.36 -0.36
Arthritis Pain -0.50 -0.35 -0.45 -0.11 -0.42
Level of Tension -0.23 -0.19 -0.17 -0.02 -0.15
Footnote: Negative correlations due to reversed scales for the HAQ and the AIMS2 (0 best) vs. RAOS and SF-36 (100 best).Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/55
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tion 43 subjects (37%) reported worst possible score
(floor effect), indicating extreme problems with squatting,
running, jumping, twisting/pivoting and kneeling at base-
line. At follow-up the proportion reporting a floor effect
decreased to 25%, indicating improvement occurring over
time as measured by this subscale. All other RAOS sub-
scales had little or no problem with floor or ceiling effects
(Table 2).
When analyzed for construct validity the highest correla-
tion occurred between subscales intended to measure sim-
ilar construct, RAOS Activities of Daily Living vs. SF-36
Physical Function (rs = 0.65) and RAOS Sport and Recrea-
tion vs. SF-36 Physical Function (rs = 0.63). For the HAQ,
the two highest correlations were HAQ vs. Activity of
Daily Living (rs = -0.72) and HAQ vs. Sport and Recreation
(rs = -0.64). Also for the AIMS2 the strongest correlation
was Walking and Bending vs. Activity of Daily Living (rs =
-0.63), all correlations were significant at p < 0.05 (Table
3).
Reliability
67 questionnaires were sent home for test-retest reliabil-
ity, 64 questionnaires were returned. Twelve subjects had
to be excluded due to too long time elapsed (more than
15 days) between test and retest. For the remaining 52
subjects there was a mean of 9 days between test and retest
(± 4 days). The random intraclass correlation coefficient
(ICC2.1) for the five subscales were Pain 0.87, Symptoms
0.85, ADL 0.92, Sport and Recreation 0.76 and for QOL
0.85. Bland and Altman plots of repeatability are given in
Figure 2. For all subscales, 95% of the differences against
the means were less than two standard deviations. Inter-
item correlation, as measured by Cronbach's alpha was
for the subscale Pain 0.92, Symptoms 0.78, ADL 0.95,
Sport and Recreation 0.92 and for QOL 0.85.
Responsiveness
The mean number of days from baseline to follow-up was
24 days (range 12–58 days). A significant improvement
was seen for all the RAOS subscales (p < 0.001) after the
intervention multidisciplinary team care (Table 4).
The effect sizes for the five RAOS subscales were: Pain
0.40, Symptoms 0.41, ADL 0.44, Sport/Recreation 0.42
and QOL 0.30. Effect sizes for comparable subscales of the
four different questionnaires are given in Figure 3.
Comparison of the RAOS to the SF-36, the HAQ and the 
AIMS2
Validity
When comparing the frequency of missing baseline data
between the RAOS and the other three questionnaires
used, the RAOS had the lowest percentage (1%) of miss-
ing values. For the SF-36, 134 items were missing (134 of
36 × 119 = 3%). Fifty-eight items were left out in the HAQ
questionnaire (58 of 20 × 119 = 2%) and in the AIMS2 70
items were lacking (70 items of 20 × 119 = 3%).
37% of the patients reported worst possible score for the
RAOS Sport and Recreation Function subscale. Other sub-
scales with substantial floor and ceiling effects were SF-36
Role Physical (64%) and Role Emotional (36%) and
AIMS2 Walking and Bending (10%). Substantial ceiling
effects, indicating no possibility to measure improve-
ment, were seen for AIMS arm function (18%), SF-36 Role
Physical (10%), Social Functioning (21%) and Role Emo-
tional (42%), Table 2.
Responsiveness
The effect sizes of the SF-36 ranged from 0.25 – 0.84,
where the subscale Bodily Pain had a larger effect size than
the corresponding subscale RAOS Pain. The SF-36 sub-
scale vitality had the highest effect size (0.84) of all sub-
scales in the study. The HAQ had a much smaller effect
size than the RAOS subscale ADL supposed to measure
similar constructs (0.14 vs. 0.44). The effect sizes of the
AIMS2 ranged from 0.11 – 0.67, with Walking and Bend-
ing at the high end and Arthritis Pain at a medium effect
size (0.43) comparable to the RAOS subscale Pain (Figure
3).
Discussion
The present and previous studies indicate that it is possi-
ble to adapt already existing outcome measures to assess
similar groups of patients [8,12,13,27]. Developing an
instrument is a time consuming process, effort and costs
can be spared if already existing questionnaires can be
adapted for use in similar groups of patients, assuming
they meet set criteria. If a questionnaire is adapted to dif-
ferent areas and found to fulfill standard requirements it
may be possible to make comparisons across diagnoses.
The RAOS has proven to be a reliable, valid and respon-
sive outcome instrument for people with chronic
inflammatory joint diseases and lower extremity dysfunc-
tion. The validation of an instrument is an ongoing proc-
ess and testing validity arises not from a single powerful
experiment, but from a series of converging experiments
[14].
A questionnaire for the lower extremity
RA, and other inflammatory joint diseases, affects both
the upper and lower extremity and to measure only lower
extremity dysfunction could be questioned. There are
however cases when the lower extremity is the key out-
come area even if there are many areas of concern. For
example interventions such as arthroplasty of the lower
extremity or physical therapy treatment mainly directed
towards the legs. Muscle dysfunction in the lowerHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/55
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Bland and Altman plots for the five subscales Figure 2
Bland and Altman plots for the five subscales.
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extremity is common among people with inflammatory
joint diseases [28,29]. A study by Ekdahl indicated that
80% of the patients with RA experienced muscle dysfunc-
tion in the lower extremities [30]. Commonly, outcome
measures validated for RA focus on evaluating upper
extremity dysfunctions. When an intervention is aiming at
restoring lower extremity dysfunction, such an instrument
is less valid and responsive and an outcome instrument
validated for the lower extremity is a better choice. The
RAOS is such an outcome measure. Also others have
acknowledged the need for evaluation of lower extremity
problems. Lately, some improvements to the HAQ have
been made; introducing activities such as participation in
sports and to do yard work [31], reflecting the need to
evaluate more vigorous activities for people with inflam-
matory joint diseases.
Validity
Assessing validity is to measure the extent to which a tech-
nique measures that which is intended [22]. The expert
panel rated the relevance of each item in the question-
naire, and found all original KOOS items being somewhat
important or important. Another way of assessing content
validity is to study the floor and ceiling effects of each
item. A ceiling effect makes impossible measuring
improvement while a floor effect makes impossible meas-
uring deterioration. A low percentage of ceiling effects
were seen for the RAOS indicating the RAOS having
potential for measuring improvement over time. The
number of patients having floor effects was small for all
RAOS subscales except Sport/Recreation where 37%
reported worst possible score at baseline. After interven-
tion however the proportion of patients reporting floor
effects was reduced to 25% indicating an improvement
taking place and thus these functions being of importance
to assess. This is in accordance with the opinion of the
expert group who rated all the items in the subscale Sport
and Recreation Function as important.
Generally it is well known that physical activity and phys-
ical function decline with age. To determine if older age or
disease activity was associated with worse scores of the
items included in the subscale Sport and Recreation Func-
tion we performed a logistic regression to analyze the risk
of having a floor effect. A worse HAQ disability score (p <
0.05), but not older age, was associated with worse scores
in items included in the subscale Sport and Recreation
Function. This indicates that the subscale Sport and Recre-
ation is as useful for patients of older age. This is in
accordance with other validation studies of the KOOS; the
subscale Sport and Recreation is as important to older
patients with osteoarthritis as it is to younger individuals
with osteoarthritis [11]. It has also previously been found
that severe functional limitation affects this subscale more
than it effects the other subscales of the KOOS [9].
Well-known and commonly used instruments for people
with chronic inflammatory joint diseases were chosen to
assess construct validity of the RAOS. In almost every
study all over the world concerning arthritis and disability
the HAQ is used and when studying health status the SF-
36 is used. The AIMS2 is also commonly used; it consists
of 12 different scales from which we choose four with the
hypothesis high, medium or low agreement with the
RAOS subscales. This is according to the suggestion of
Liang and Jette; to fully establish construct validity the
investigator must also demonstrate what variables are
uncorrelated with the construct of interest [32]. In this
study the correlations were as expected high when
addressing subscales of similar construct and lower when
compared to subscales assessing different constructs.
However, to fully validate an outcome instrument it has to
Table 4: Mean (SD) of the RAOS at baseline and after the 
intervention multidiscipline care at Spenshult. 0–100 worst to 
best scale.
RAOS Baseline Follow up P-value
Pain 51(21) 60(21) <0.001
Symptoms 52(19) 60(20) <0.001
ADL 50(21) 59(23) <0.001
Sport/Rec 18(22) 27(29) <0.001
QOL 35(21) 41(23) <0.001
Effect size after intervention multidiscipline care for the five  dimensions of the RAOS and corresponding dimensions of  SF-36, HAQ and AIMS2 Figure 3
Effect size after intervention multidiscipline care for the five 
dimensions of the RAOS and corresponding dimensions of 
SF-36, HAQ and AIMS2.
Effect size 
0 0,2 0,4 0,6 0,8 1
AIMS2 level of tension
RAOS QOL
SF-36 role physical
RAOS Sport/Rec
AIMS2 walking/bending
HAQ
SF-36 physical function
RAOS ADL
RAOS symptoms
AIMS2 art. pain
SF-36 bodily pain
RAOS painHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/55
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perform as expected in different settings [14]. Further
studies are needed to enlighten this question.
Reliability
Reliability is a measure of the consistency with which a
technique yields the same results on repeated administra-
tion [14]. Test-retest was determined with a range of 1 –
15 days. The opinions regarding the appropriate interval
vary from an hour to a year depending on the task, but a
test-retest interval of two to 14 days is common for this
type of questionnaire [14]. In our study one administra-
tion of the test-retest was given at home and the other one
was given at the hospital. The difference in administration
modes used may affect the reliability, but if so probably to
the worse.
The test-retest reliability was high enough (ICC >0.85) to
allow comparisons over time on an individual level for all
subscales but Sport and Recreation (ICC 0.76) [24,25].
When studied in patients with knee injury, the Sport and
Recreation Function subscale was more reliable (ICC
0.85) than in the present study, however compared to the
other KOOS subscales it was less reliable [9]. Possibly a
greater variability is to be expected when assessing more
difficult physical function compared to activities of daily
living and pain. In the revised and expanded version of
the AIMS2 the test-retest reliability (ICC) for all 12 sub-
scales ranged from 0.78 to 0.94, with a high correlation
for the subscale Walking and Bending (ICC 0.92) [20].
To test for factors affecting the variability of the Sport and
Recreation Function we checked for the impact of disease
disability (HAQ score above median), older age, gender
and disease duration. None of these factors were associ-
ated with increased variability of the subscale Sport and
Recreation. However, it is well known that scales with
more items have better reliability [14]. When comparing
the Bland-Altman plots of the five RAOS subscales it is
clearly seen that the fewer items of the subscale the worse
test-retest reliability. To improve the reliability of the
Sport and Recreation subscale, possibly items should be
added. This strategy would however increase the length of
the questionnaire. It should be determined if the reliabil-
ity of the Sport and Recreation Function subscale could be
improved to allow also comparisons on an individual
level.
If the inventory of a questionnaire is relatively homogene-
ous and unambiguous, then the inter-item correlation
will be high. The inter-item correlations of the five RAOS
subscales were high enough to indicate homogeneity.
According to Streiner a too high alpha (>0.90) may indi-
cate item redundancy [14], which could be the case of the
RAOS subscale ADL. The RAOS subscale ADL is equiva-
lent to the WOMAC subscale Function. Item redundancy
for the WOMAC subscale Function has previously also
been suggested by others [33].
Responsiveness
A small to medium effect size is to be expected when stud-
ying interventions such as multidimensional care and dif-
ferent forms of arthritis [21,34]. The value of HAQ as a
group outcome measure is well established, the usefulness
of monitoring individual HAQ scores in a clinical setting
has been questioned [35]. A study by van den Ende et al.
concluded that the HAQ is not an appropriate instrument
to detect changes in physical impairments due to short-
term exercise therapy [36], a finding confirmed by the cur-
rent study. All the RAOS subscale scores improved signif-
icantly due to intervention and the RAOS effect sizes
ranged from 0.30–0.44 indicating the RAOS being a valid
measure for change over time. It is interesting to notice
that the multidisciplinary care intervention improved not
only difficulty with activities of daily living (as measured
by the subscale ADL) but also improved more difficult
physical functions (as measured by the subscale Sport and
Recreation Function) to the same extent (as measured by
similar effect sizes of the two subscales). By most other
outcome measures this improvement would have
remained undetected.
The multidisciplinary care given to the study subjects
aimed at improving upper and lower extremity function,
which could explain the generic SF-36 being more respon-
sive than the RAOS with regard to the subscales Bodily
Pain and Role Physical. Using multidisciplinary team care
for validation of an instrument assessing only lower
extremity function could be considered a limitation. It is
thus of interest to note that the effect sizes of the RAOS
were higher than for the HAQ, an instrument taking also
other aspects into account and frequently used for assess-
ment of multidisciplinary care in arthritis. The effect size
of AIMS2 Arthritis Pain was of the same magnitude as the
RAOS subscale Pain. The effect size of AIMS2 Walking and
Bending was higher than of the corresponding subscales
RAOS ADL and the SF-36 Physical Function. One possible
explanation is the difference in response options in the
questionnaires. The response alternatives in the AIMS2 are
based on frequency of the difficulty and the SF-36 and the
RAOS response alternatives concerns intensity of the diffi-
culty. The subscale QOL was the least responsive of the
RAOS instrument. As seen in studies on hip and knee
replacement, this and similar subscales tends to need
longer time to change than the 3–4 weeks in the present
study [11,13].
Future application of the RAOS
Self-administered questionnaires can be generic or dis-
ease-specific. The advantage of using generic question-
naires such as SF-36 is that comparisons can be madeHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/55
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across diagnoses, and thus be a tool for health care plan-
ners. However, adapting a disease-specific questionnaire
for musculoskeletal problems due to different origins
could make comparisons across these diagnoses possible.
The RAOS is such an adapted questionnaire also available
for patients whose problems origin from the knee, hip
and foot [7,12,13]. The RAOS includes the WOMAC,
which is a widely used self-administered questionnaire for
patients with osteoarthritis (OA) of either the hip or knee
joint [8] validated also for patients with RA [27]. Adding
dimensions such as Sport and Recreation Function and
leg-related Quality of Life to the WOMAC can give a more
descriptive picture of a subject, or a fuller picture of the
impact of an intervention. We suggest using the RAOS to
describe and follow patients with arthritis, especially
when undergoing interventions aiming at restoring lower
extremity function.
Conclusion
The present and previous studies indicate that it is possi-
ble to adapt already existing outcome measures to assess
other groups of patients with musculoskeletal difficulties.
The Rheumatoid and Arthritis Outcome Score (RAOS) is
a reliable, valid and responsive outcome instrument for
people with inflammatory joint diseases and lower
extremity dysfunction undergoing a multidisciplinary care
intervention. To fully establish the use of the RAOS ques-
tionnaire further studies are needed.
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